STOCK TITAN
  1. Home
  2. News
  3. SNY

Sanofi - SNY STOCK NEWS

Welcome to our dedicated news page for Sanofi (Ticker: SNY), a resource for investors and traders seeking the latest updates and insights on Sanofi.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sanofi's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sanofi's position in the market.

News
Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups
Rhea-AI Summary
Sanofi launches Verorab® in the UK, an inactivated rabies vaccine for pre-exposure and post-exposure prophylaxis. Clinical trials show high immune response and long-term protection. Rabies is fatal but preventable, with millions vaccinated worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
-
News
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
Rhea-AI Summary
Teva Pharmaceuticals announces positive safety and tolerability data for anti-TL1A (TEV-'574) in inflammatory bowel disease, demonstrating rapid and sustained suppression of free TL1A. The asset shows a well-tolerated safety profile and supports ongoing Phase 2b clinical investigation. Teva also disclosed a collaboration deal with Sanofi for co-development and co-commercialization of anti-TL1A (TEV-'574) for UC and CD, with significant financial implications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
-
News
Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases
Rhea-AI Summary
Synthekine Inc. announced a collaboration with Sanofi to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases. Synthekine will receive a $40 million upfront payment and is eligible for additional milestones and royalties on net sales. The collaboration aims to develop selective agonists that expand therapeutic index, focusing on advancing Synthekine’s multiple approaches to optimizing IL-10. Sanofi will assume sole responsibility for subsequent preclinical, clinical, and commercial activities for the IL-10 therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
News
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
Rhea-AI Summary
Inhibrx, Inc. (Nasdaq: INBX) and Sanofi (Nasdaq: SNY) have entered into a definitive agreement under which Sanofi will acquire all assets and liabilities associated with INBRX-101. Inhibrx shareholders will receive $30 per share in cash, a CVR of $5, and 0.25 shares in New Inhibrx. Sanofi will pay off Inhibrx's outstanding debt and capitalize New Inhibrx with $200 million in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.91%
Tags
none
-
News
Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target
Rhea-AI Summary
Scribe Therapeutics Inc. (SNY) announces that Sanofi has exercised its option for a second target as part of the companies' research collaboration to develop in vivo CRISPR-based therapeutics. The ongoing collaboration aims to advance in vivo genetic medicines using Scribe’s CRISPR by Design™ approach. Scribe will receive a milestone payment associated with the second target nomination and be eligible to receive additional development and commercial milestones upon advancement of the program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
-
News
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
Rhea-AI Summary
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced that Sanofi has exercised its option to license a natural killer (NK) cell engager program from Innate’s ANKET® platform. Sanofi will be responsible for all development, manufacturing, and commercialization of the program. Innate will receive a €15m payment for the exercise of this option and is eligible for up to €1.35bn in total milestones plus royalties on potential net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.8%
Tags
none
News
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
Rhea-AI Summary
Teva Pharmaceuticals (TEVA) closes collaboration deal with Sanofi (SAN, SNY) to co-develop and co-commercialize asset TEV '574, currently in Phase 2b clinical trials for ulcerative colitis and Crohn's disease. Teva to receive $500 million upfront payment and up to $1 billion in milestones. Joint development and profit sharing agreement with Sanofi. Estimated 10 million people worldwide live with IBD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
-
News
Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities
Rhea-AI Summary
Sanofi has announced the winners of its 2023 Health Equity Accelerator Awards, honoring 10 nonprofit organizations that exemplify the company's ambition to provide equitable access to healthcare using innovative solutions for hard-to-solve health disparities. Each winning organization will receive $50,000 from Sanofi and will be able to leverage the company's expertise through this partnership. In addition to the awards, Sanofi has launched a health equity Community of Practice to connect advocacy groups and share best practices. The company will also host a special event in January 2024 to celebrate the advocacy groups working to advance health equity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
none
-
News
Sanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S.
Rhea-AI Summary
Sanofi launches 'The 1 Pledge' movement to educate and encourage families to get screened for type 1 diabetes. The movement is supported by celebrities including Usher Raymond IV. Type 1 diabetes can be detected before symptoms arise and affects approximately 1.45 million Americans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
none
News
GoodRx Announces New Way for Consumers to Access Sanofi’s Lantus for $35 at Over 70,000 Pharmacies Nationwide
Rhea-AI Summary
GoodRx partners with Sanofi to offer affordable access to Lantus insulin for people with diabetes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
none
Stock SNY logo
Sanofi

Nasdaq:SNY

SNY Rankings

#99 Ranked by Market Cap
#2006 Ranked by Stock Gains
#755 Ranked by Dividends

SNY Stock Data

116.17B
1.10B
0%
9.94%
0.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
France
Paris

About SNY

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo